AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$SNTI

Senti Biosciences Holdings, Inc.

Price · $SNTIvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $SNTI in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $SNTI in the last 30 days.

Top stories · $SNTIMore →
APR 9·TradingViewHigh

SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with excellent safety in R/R AML Phase 1 trial

SENTI-202, an off-the-shelf logic-gated CAR-NK cell therapy developed by Senti Biosciences (SNTI), demonstrated significant efficacy in a Phase 1 trial for high-risk relapsed/refractory Acute Myeloid Leukemia (R/R AML) patients. The therapy achieved a 50% overall response rate (ORR) and a 42% complete remission/complete remission with partial hematologic recovery (CR/CRh), with all CRs being MRD-negative, alongside strong safety. Senti Biosciences plans a pivotal trial for 2026 and intends to expand the platform into solid tumors.

APR 1·Stock Titan

Senti Biosciences (SNTI) holder NEA discloses 3.78M-share, 12.1% stake

New Enterprise Associates 15, L.P. (NEA) has filed an amended Schedule 13D/A, disclosing a 12.1% stake in Senti Biosciences (SNTI), equating to 3,775,615 shares. The decrease in their percentage ownership (by more than 1%) is due to an increase in Senti's outstanding shares, not a result of NEA buying or selling shares. NEA holds these shares for investment purposes and currently has no specific plans for corporate actions.

NOV 13·GlobeNewswire

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia ( AML ) at the American Society of Hematology Annual Meeting in December

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Senti Biosciences, Inc. ( Nasdaq: SNTI ) ( "Senti Bio" ) , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for ...

News on $SNTI

All news →